Roivant Sciences (ROIV) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Roivant Sciences

NasdaqGS•Healthcare•Biotechnology

$39.77-0.21(-0.01%)Market closed

Market Cap

$28.67B

P/S

3805.8x

P/B

6.8x

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

How this company scores

AverageMetricSide Score: 51/100

Strongest: Growth (16/25); weakest: Cash & Earnings Quality (8/25).

Profitability12/25

Growth16/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Growing revenueInterest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1.6x5y range 1.6x – 1.8x

P/S · 3805.8x5y range 35.5x – 3805.8x

Currently above its 12-quarter median.

P/B · 6.8x5y range 1.4x – 9.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $28.67B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $7.53M
Q. Revenue: $1.44M
TTM EBITDA: $-591.68M
TTM Op. Income: $-596.14M
Q. Op. Income: $-365.99M
TTM Net Income: $-266.25M
Q. Net Income: $-189.84M
EPS: $-0.26
Shares Out.: $720.78M

$7.53M in TTM revenue grew 131.5% YoY, reaching $1.44M last quarter. TTM EBITDA of $-591.68M and TTM operating income of $-596.14M show growth is flowing through to the bottom line. However, net income is negative at $266.25M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 132% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -25339.3%
Op. Margin: -25380.9%
Net Margin: -13164.8%

Op. margin of -25380.9% is down 12250.9% YoY — costs are rising relative to revenue. Net margin at -13164.8% Over the past year, operating margin is down 93% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 3805.8x
P/B Ratio: 6.8x

P/S of 3805.8x and P/B of 6.8x. P/S is high, meaning growth expectations are priced in. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $5.31B
Cash: $1.25B
Long-Term Debt: N/A
Book Value: $4.23B
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-270.50M
TTM Free Cash Flow: $-821.06M
FCF Margin: -10901.0%
FCF / Net Income: 3.1

TTM FCF of $-821.06M on $-270.50M in operating cash flow. The FCF / Net Income ratio of 3.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 4% — a weakening trend.